Evidence map›Paper›PMID 42037123›Full record

ArticlePhytotherapy research : PTR2026

The Allium cepa Derived Compound Propyl Propane Thiosulfonate (PTSO) Improves Tumorigenesis Due to Its Immunomodulatory Effect: A Preclinical Study.

María Jesús Rodríguez-Sojo, Laura Hidalgo-García, Jose Alberto Molina-Tijeras, Laura López-Escanez, Luckman Gbati, Teresa Vezza, Patricia Diez-Echave, Antonio Jesús Ruiz-Malagón, Jorge García-García, Federico García and 7 more

Abstract read
In one paragraph

Article in Phytotherapy research : PTR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

María Jesús Rodríguez-SojoDepartment of Pharmacology, Center for Biomedical Research (CIBM), University of Granada, Granada, Spain.ORCID https://orcid.org/0000-0002-1693-505X
Laura Hidalgo-GarcíaDepartment of Pharmacology, Center for Biomedical Research (CIBM), University of Granada, Granada, Spain.ORCID https://orcid.org/0000-0002-5529-171X
Jose Alberto Molina-TijerasDepartment of Pharmacology, Center for Biomedical Research (CIBM), University of Granada, Granada, Spain.ORCID https://orcid.org/0000-0003-1554-9226
Laura López-EscanezDepartment of Pharmacology, Center for Biomedical Research (CIBM), University of Granada, Granada, Spain.ORCID https://orcid.org/0009-0006-1480-1062
Luckman GbatiDepartment of Pharmacology, Center for Biomedical Research (CIBM), University of Granada, Granada, Spain.ORCID https://orcid.org/0009-0009-9301-632X
Teresa VezzaDepartment of Pharmacology, Center for Biomedical Research (CIBM), University of Granada, Granada, Spain.ORCID https://orcid.org/0000-0002-9780-0180
Patricia Diez-EchaveAllergy Research Group, IBIMA Plataforma BIONAND, Málaga, Spain.ORCID https://orcid.org/0000-0003-4493-3091
Antonio Jesús Ruiz-MalagónDepartment of Pharmacology, Center for Biomedical Research (CIBM), University of Granada, Granada, Spain.ORCID https://orcid.org/0000-0003-4323-650X
Jorge García-GarcíaInstituto de Investigación Biosanitaria de Granada (Ibs.GRANADA), Granada, Spain.ORCID https://orcid.org/0000-0003-0925-9441
Federico GarcíaInstituto de Investigación Biosanitaria de Granada (Ibs.GRANADA), Granada, Spain.ORCID https://orcid.org/0000-0001-7611-781X
Alberto BañosDMC Research Center, Granada, Spain.
Lidia Gil-MartínezDMC Research Center, Granada, Spain.
Rocío López-PosadasDeutsches Zentrum Immuntherapie (DZI), Erlangen, Germany.
Markus F NeurathDeutsches Zentrum Immuntherapie (DZI), Erlangen, Germany.
Julio GálvezDepartment of Pharmacology, Center for Biomedical Research (CIBM), University of Granada, Granada, Spain.ORCID https://orcid.org/0000-0001-6876-3782
María Elena Rodríguez-CabezasDepartment of Pharmacology, Center for Biomedical Research (CIBM), University of Granada, Granada, Spain.ORCID https://orcid.org/0000-0001-9085-8147
Alba Rodríguez-NogalesDepartment of Pharmacology, Center for Biomedical Research (CIBM), University of Granada, Granada, Spain.ORCID https://orcid.org/0000-0003-1927-0628

Funding

Centro para el Desarrollo Tecnológico Industrial CULTUREDMEAT-Project-MIG-20201012Instituto de Salud Carlos III CD22/00112Instituto de Salud Carlos III CD23/00102Instituto de Salud Carlos III CD23/00117Instituto de Salud Carlos III CP22/00153Instituto de Salud Carlos III IFI21/00030Instituto de Salud Carlos III PI19/01058Instituto de Salud Carlos III PI20/01447
6 · The paper itself

Abstract

Allium-derived organosulfur compounds offer significant health benefits. Specifically, PTSO, an organosulfur compound extracted from Allium cepa , has demonstrated immunomodulatory and prebiotic properties. However, its effects on tumorigenesis and gut dysbiosis in colitis-associated colorectal cancer (CAC) remain unexplored. This study aimed to investigate the impact of two PTSO formulations, free (FP) and encapsulated (EP), on a murine model of CAC focusing on their impact on the immune system and gut microbiome. The antitumor effect of PTSO was characterized in vitro in HCT116 cells and in a CAC murine model induced by the administration of azoxymethane and dextran sulfate sodium. FP and EP were administered orally throughout the assay and 5-fluorouracil was used as a control. FP and EP were effective in reducing tumor burden, with EP showing a greater positive impact on tumorigenesis by reducing both tumor number and size, likely due to enhanced bioavailability. PTSO induced apoptosis through oxidative stress mechanisms and modulated key pathways like STAT3, PI3K/mTOR, and Wnt/β-catenin. Additionally, PTSO, especially EP, exhibited an immunomodulatory effect on myeloid and lymphoid populations and hindered the release of cytokines that prompted inflammation and cancer progression. PTSO also enhanced gut barrier integrity, increased the abundance of beneficial bacteria, like Akkermansia, Leuconostoc mesenteroides , and Weissella confusa, and the release of short-chain fatty acids (SCFAs). This study highlights the potential of PTSO, particularly in its encapsulated form, as a promising therapeutic agent for CRC by targeting both tumor growth and the underlying inflammatory processes while restoring gut microbiota balance.

Indexed as

CarcinogenesisColitis-Associated NeoplasmsImmunologic FactorsOnionsThiosulfonic AcidsAnimalsApoptosisAzoxymethaneColitisDextran SulfateDisease Models, AnimalGastrointestinal MicrobiomeHCT116 CellsHumansMaleMiceAzoxymethaneDextran SulfateImmunologic FactorsThiosulfonic Acidscolitis‐associated colorectal cancergut barrier integrityimmunomodulationintestinal microbiotapropyl propane thiosulfonateshort‐chain fatty acids

Identifiers

PMID42037123
PMCPMC13340989

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.